|
| Press Releases |
|
 |
|
| Friday, July 7, 2023 |
|
|
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI more info >> |
|
| Friday, June 30, 2023 |
|
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
| Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
| Thursday, June 22, 2023 |
|
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
| Monday, June 12, 2023 |
|
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
| Thursday, June 8, 2023 |
|
|
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea |
| This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries. more info >> |
|
| Friday, June 2, 2023 |
|
|
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting |
| Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States. more info >> |
|
| Friday, May 26, 2023 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
| Thursday, May 25, 2023 |
|
|
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria |
| Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. more info >> |
|
| Wednesday, May 24, 2023 |
|
|
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6. more info >> |
|
| Saturday, May 20, 2023 |
|
|
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Four HK designer labels shine at London Fashion Week
Feb 22, 2025 22:56 HKT/SGT
|
|
|
Dollamur Announces United World Wrestling Approval Through 2028
Feb 22, 2025 22:54 HKT/SGT
|
|
|
Yashaa Global Capital Secures Financial Services Permission to Establish a Global Sports VC Fund
Feb 22, 2025 20:11 HKT/SGT
|
|
|
AsiaMedic and Sunway launch new Medical Diagnostic Imaging Centre in Novena 
Feb 22, 2025 18:00 HKT/SGT
|
|
|
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026
Feb 22, 2025 4:50 JST
|
|
|
Alexis Mc Allister Announces as Jeton's Latest Brand Ambassador
Feb 21, 2025 23:00 HKT/SGT
|
|
|
NaaS Technology Launches $10 Million Share Repurchase Plan Boosting Market Confidence
Feb 21, 2025 21:09 HKT/SGT
|
|
|
Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint
Feb 21, 2025 19:40 JST
|
|
|
Carl Zeiss Honors EuroEyes International for Exceptional Milestone in AT LISA(R) Trifocal Lens Implantations
Feb 21, 2025 18:29 HKT/SGT
|
|
|
Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions
Feb 21, 2025 19:11 JST
|
|
|
Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation
Feb 21, 2025 15:01 JST
|
|
|
NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award
Feb 21, 2025 14:39 JST
|
|
|
NEC Develops Near Real-time RIC for High Performance 5G vRAN
Feb 21, 2025 12:00 JST
|
|
|
Igloo kicks off 2025 with Multi-market Partnership Wins and Chief Distribution Officer Appointment
Feb 21, 2025 09:00 HKT/SGT
|
|
|
Giftify, Inc. Announces Smart Savings Solution for Popular GLP-1 Diabetes and Weight Loss Medications
Feb 21, 2025 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
